186 related articles for article (PubMed ID: 28471257)
21. Past, Present, and Future of Targeting Ras for Cancer Therapies.
Tan Z; Zhang S
Mini Rev Med Chem; 2016; 16(5):345-57. PubMed ID: 26423695
[TBL] [Abstract][Full Text] [Related]
22. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial clearance by the STK38 kinase supports oncogenic Ras-induced cell transformation.
Bettoun A; Joffre C; Zago G; Surdez D; Vallerand D; Gundogdu R; Sharif AA; Gomez M; Cascone I; Meunier B; White MA; Codogno P; Parrini MC; Camonis JH; Hergovich A
Oncotarget; 2016 Jul; 7(28):44142-44160. PubMed ID: 27283898
[TBL] [Abstract][Full Text] [Related]
24. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
25. ERK-regulated αB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo.
Malin D; Strekalova E; Petrovic V; Rajanala H; Sharma B; Ugolkov A; Gradishar WJ; Cryns VL
Oncogene; 2015 Nov; 34(45):5626-34. PubMed ID: 25684139
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic strategies to target RAS-mutant cancers.
Ryan MB; Corcoran RB
Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
[TBL] [Abstract][Full Text] [Related]
27. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
Delire B; Stärkel P
Eur J Clin Invest; 2015 Jun; 45(6):609-23. PubMed ID: 25832714
[TBL] [Abstract][Full Text] [Related]
28. [Targeting the RAS signalling pathway in cancer].
Mansi L; Viel E; Curtit E; Medioni J; Le Tourneau C
Bull Cancer; 2011 Oct; 98(9):1019-28. PubMed ID: 21715253
[TBL] [Abstract][Full Text] [Related]
29. Targeting anoikis resistance in prostate cancer metastasis.
Sakamoto S; Kyprianou N
Mol Aspects Med; 2010 Apr; 31(2):205-14. PubMed ID: 20153362
[TBL] [Abstract][Full Text] [Related]
30. RAS-mediated oncogenic signaling pathways in human malignancies.
Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S
Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560
[TBL] [Abstract][Full Text] [Related]
31. K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival.
Ninomiya Y; Kato K; Takahashi A; Ueoka Y; Kamikihara T; Arima T; Matsuda T; Kato H; Nishida J; Wake N
Cancer Res; 2004 Apr; 64(8):2759-65. PubMed ID: 15087391
[TBL] [Abstract][Full Text] [Related]
32. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
33. Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.
Lu S; Jang H; Gu S; Zhang J; Nussinov R
Chem Soc Rev; 2016 Sep; 45(18):4929-52. PubMed ID: 27396271
[TBL] [Abstract][Full Text] [Related]
34. Tumor suppressor protein kinase Chk2 is a mediator of anoikis of intestinal epithelial cells.
Yoo BH; Berezkin A; Wang Y; Zagryazhskaya A; Rosen KV
Int J Cancer; 2012 Jul; 131(2):357-66. PubMed ID: 21834075
[TBL] [Abstract][Full Text] [Related]
35. Chalcones bearing a 3,4,5-trimethoxyphenyl motif are capable of selectively inhibiting oncogenic K-Ras signaling.
Kovar SE; Fourman C; Kinstedt C; Williams B; Morris C; Cho KJ; Ketcha DM
Bioorg Med Chem Lett; 2020 Jun; 30(11):127144. PubMed ID: 32276831
[TBL] [Abstract][Full Text] [Related]
36. Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target.
Chen M; Peters A; Huang T; Nan X
Mini Rev Med Chem; 2016; 16(5):391-403. PubMed ID: 26423697
[TBL] [Abstract][Full Text] [Related]
37. Targeting the RAS oncogene.
Takashima A; Faller DV
Expert Opin Ther Targets; 2013 May; 17(5):507-31. PubMed ID: 23360111
[TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway.
Luey BC; May FE
Mol Cancer; 2016 Jan; 15():8. PubMed ID: 26801096
[TBL] [Abstract][Full Text] [Related]
39. Blocking oncogenic Ras signaling for cancer therapy.
Adjei AA
J Natl Cancer Inst; 2001 Jul; 93(14):1062-74. PubMed ID: 11459867
[TBL] [Abstract][Full Text] [Related]
40. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
